Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease

NCT00911495 is registered in ClinicalTrials.gov with GlycoMimetics Incorporated as lead sponsor.

NCT NCT00911495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00911495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease
Lead sponsor
GlycoMimetics Incorporated
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2009
Completion date
September 30, 2010
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease